
David M Routman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3720895/publications.pdf Version: 2024-02-01



ΠΑΝΙΟ Μ ΡΟΠΤΜΑΝ

#	Article	IF	CITATIONS
1	A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer. Advances in Radiation Oncology, 2019, 4, 63-69.	1.2	75
2	Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity. Journal of Neuro-Oncology, 2018, 139, 421-429.	2.9	74
3	The growing importance of lesion volume as a prognostic factor in patients with multiple brain metastases treated with stereotactic radiosurgery. Cancer Medicine, 2018, 7, 757-764.	2.8	45
4	Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram. Practical Radiation Oncology, 2020, 10, e16-e26.	2.1	42
5	Preoperative Stereotactic Radiosurgery for Brain Metastases. Frontiers in Neurology, 2018, 9, 959.	2.4	41
6	Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. Radiotherapy and Oncology, 2020, 147, 64-74.	0.6	34
7	Detectable Postoperative Circulating Tumor Human Papillomavirus DNA and Association with Recurrence in Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2022, 113, 530-538.	0.8	31
8	Relapse Rates With Surgery Alone in Human Papillomavirus–Related Intermediate- and High-Risk Group Oropharynx Squamous Cell Cancer: A Multi-Institutional Review. International Journal of Radiation Oncology Biology Physics, 2017, 99, 938-946.	0.8	30
9	A Comparison of Patient-Reported Health-Related Quality of Life During Proton Versus Photon Chemoradiation Therapy for Esophageal Cancer. Practical Radiation Oncology, 2019, 9, 410-417.	2.1	20
10	Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. Brachytherapy, 2019, 18, 1-7.	0.5	19
11	Human papillomavirus oropharynx carcinoma: Aggressive deâ€escalation of adjuvant therapy. Head and Neck, 2021, 43, 229-237.	2.0	19
12	IMPT versus VMAT for Pelvic Nodal Irradiation in Prostate Cancer: A Dosimetric Comparison. International Journal of Particle Therapy, 2019, 5, 11-23.	1.8	16
13	Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis. Cancer Journal (Sudbury,) Tj ETQq1 I	0.784314	rg_{15}^{BT} /Over
14	Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery. Journal of Neurosurgery, 2016, 125, 31-39.	1.6	13
15	Mucoepidermoid carcinoma of the parotid gland: <scp>Twentyâ€year</scp> experience in treatment and outcomes. Head and Neck, 2021, 43, 2663-2671.	2.0	11
16	Estimated Cost of Circulating Tumor DNA for Posttreatment Surveillance of Human Papillomavirus–Associated Oropharyngeal Cancer. JAMA Network Open, 2022, 5, e2144783.	5.9	11
17	A Multi-Institutional Analysis of Radiation Dosimetric Predictors of Toxicity After Trimodality Therapy for Esophageal Cancer. Practical Radiation Oncology, 2021, 11, e415-e425.	2.1	10
18	Patient-reported outcomes of catheter-based accelerated partial breast brachytherapy and whole breast irradiation, a single institution experience. Breast Cancer Research and Treatment, 2018, 169, 189-196.	2.5	8

David M Routman

#	Article	IF	CITATIONS
19	T cell fraction impacts oncologic outcomes in human papillomavirus associated oropharyngeal squamous cell carcinoma. Oral Oncology, 2020, 111, 104894.	1.5	8
20	Comparing bowel and urinary domains of patientâ€reported quality of life at the end of and 3 months post radiotherapy between intensityâ€modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. Cancer Medicine, 2020, 9, 7925-7934.	2.8	6
21	Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience. Clinical and Translational Radiation Oncology, 2021, 28, 17-23.	1.7	6
22	The Importance of Verification CT-QA Scans in Patients Treated with IMPT for Head and Neck Cancers. International Journal of Particle Therapy, 2020, 7, 41-53.	1.8	6
23	Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma. Journal of Neuro-Oncology, 2022, 158, 323-330.	2.9	5
24	Disease Profile and Oncologic Outcomes After Delayed Diagnosis of Human Papillomavirus–Associated Oropharyngeal Cancer. Otolaryngology - Head and Neck Surgery, 2021, 165, 830-837.	1.9	4
25	Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer. Oral Oncology, 2021, 123, 105625.	1.5	4
26	An comparison of acute toxicities and <scp>patientâ€reported</scp> outcomes between intensityâ€modulated proton therapy and volumetricâ€modulated arc therapy after ipsilateral radiation for head and neck cancers. Head and Neck, 2022, 44, 359-371.	2.0	4
27	Proton therapy for the treatment of inflammatory breast cancer. Radiotherapy and Oncology, 2022, 171, 77-83.	0.6	4
28	Human Papillomavirus–Associated Anogenital Pathology in Females With HPV-Positive Oropharyngeal Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2021, 164, 369-374.	1.9	2
29	Second Primary Tumors in Patients Presenting With Unilateral HPV â€Associated Tonsillar Squamous Cell Carcinoma. Laryngoscope, 2021, , .	2.0	2
30	Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. Bladder, 2018, 5, e34.	0.2	2
31	Outcomes and Patterns of Recurrence for Anaplastic Thyroid Cancer Treated With Comprehensive Chemoradiotherapy. Practical Radiation Oncology, 2022, 12, 113-119.	2.1	2
32	In Reply to Garden. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1296-1297.	0.8	1
33	Anaplastic Ependymoma and Posterior Fossa Grouping in a Patient With H3K27ME3 Loss of Expression but Chromosomal Imbalance. Advances in Radiation Oncology, 2019, 4, 466-472.	1.2	1
34	The impact of tumor infiltrating lymphocytes (TILs) on disease progression in human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma Journal of Clinical Oncology, 2021, 39, 6049-6049.	1.6	1
35	Oncologic Outcomes for Head and Neck Skin Malignancies Treated with Protons. International Journal of Particle Therapy, 2021, 8, 294-303.	1.8	1
36	Predictors of lymphopenia in esophageal cancer patients receiving photon or proton radiation therapy: A dosimetric analysis Journal of Clinical Oncology, 2019, 37, 147-147.	1.6	1

David M Routman

#	Article	IF	CITATIONS
37	An artificial intelligence-enabled analysis of ECG changes after androgen deprivation therapy (ADT) for prostate cancer Journal of Clinical Oncology, 2020, 38, e17535-e17535.	1.6	1
38	Salvage Radiosurgery for Recurrent Supratentorial Primitive Neuroectodermal Tumors: A Single Institutional Series and Review of the Literature. Stereotactic and Functional Neurosurgery, 2021, 99, 405-411.	1.5	0
39	Acute patient-reported toxicities after proton therapy or intensity-modulated radiotherapy for prostate cancer Journal of Clinical Oncology, 2020, 38, 305-305.	1.6	Ο
40	The Number of Radiographically Positive Lymph Nodes Further Stratifies Patient Survival Among Clinical N1 Patients With Human Papillomavirus–Associated Oropharyngeal Cancer. Advances in Radiation Oncology, 2022, 7, 100926.	1.2	0